Menu

Press Releases

Sangamo BioSciences Announces Presentation Of First Demonstration Of In Vivo Efficacy Of Novel ZFP Therapeutic® For Huntington’s Disease

, , ,

Approach Selectively Represses Only the Disease-Causing Gene Resulting in Statistically Significant Effects on Symptoms and Other Biomarkers of Disease in Animal Models RICHMOND, Calif., Nov. 12, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that positive preclinical data from their joint program with Shire plc to develop a novel ZFP Therapeutic® approach to Huntington’s disease (HD) were presented […]

Cardinal Health Foundation Calls for Applicants for Patient Safety Grants

, ,

E3 Grant Program helps health care institutions improve effectiveness, efficiency and excellence DUBLIN, Ohio, Nov. 11, 2013 /PRNewswire/ — The Cardinal Health Foundation is currently accepting applications for grant funding to help U.S., Canadian and Puerto Rican hospitals, health systems, community health clinics and other non-profit health care institutions improve the efficiency and quality of […]

MERZ PHARMA GROUP ACQUIRES SWISS AESTHETICS COMPANY ANTEIS S.A.

, ,

GREENSBORO, N.C. – BUSINESS WIRE – Merz Pharma Group (Frankfurt am Main) announced that it has entered into a definitive agreement to acquire Anteis S.A., a Swiss company which specializes in the development, manufacture and commercialization of medical devices in the area of aesthetics. With products available in more than 90 countries on five continents, Anteis has been recognized as […]

Novartis announces divestiture of its blood transfusion diagnostics unit to Grifols

, ,

Spain-based Grifols to acquire Novartis blood transfusion diagnostics unit for USD 1.675 billion Divestiture further enhances Novartis focus on strategic businesses Basel, November 11, 2013 – Novartis announced a definitive agreement to divest its blood transfusion diagnostics unit to Grifols for USD 1.675 billion. This transaction, requiring customary regulatory approvals, is expected to be completed […]

Forest Laboratories Names A. Robert D. Bailey Senior Vice President, Chief Legal Officer and General Counsel

, , ,

NEW YORK–November 11, 2013–(BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) today announced that Robert Bailey was appointed Senior Vice President, Chief Legal Officer General Counsel. In this role, Bailey will be responsible to manage the legal affairs of the Company, and will also serve as the company’s Corporate Secretary. Bailey will report to Brent Saunders, Chief Executive […]

Two Papers From a Large Multi-site Study Further Demonstrate Efficacy and Quality of Life Benefits for Prostate Cancer Patients Treated with Accuray’s CyberKnife® System

, , , ,

UCLA Researchers Evaluate Long-term Outcomes of More than 1,000 Patients from Multiple Institutions SUNNYVALE, Calif., November 7, 2013 – Accuray Incorporated (Nasdaq: ARAY), announced today the publication of two papers stemming from a large multi-center study of CyberKnife® stereotactic body radiotherapy (SBRT) led by investigators at the University of California, Los Angeles (UCLA). The first […]

Forest Laboratories, Inc. Announces Settlement of BYSTOLIC® Patent Litigation

, , ,

NEW YORK–November 7, 2013–(BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) and Forest Laboratories Holdings, Ltd. (collectively, “Forest”) announced today that they have entered into a settlement agreement with Actavis, Inc. and related companies and subsidiaries thereof, in patent infringement litigation brought by Forest in response to Actavis’s abbreviated new drug application (“ANDA”) seeking approval to market generic […]

Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection

, , , ,

Data Demonstrate ZFN-dependent CCR5 Modification of Long-lived Central Memory and Stem-like T-cells RICHMOND, Calif., Nov. 4, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of clinical data from its program to develop a ZFP Therapeutic® for HIV/AIDS.  The data demonstrate a reduction in the HIV DNA reservoir since receiving SB-728-T in seven of nine HIV-infected subjects […]

New Study Finds Robotic-Assisted Lung Surgery Offers Improved Patient Outcomes Compared to Open Surgery

, , , , ,

SUNNYVALE, Calif., Nov. 4, 2013 (GLOBE NEWSWIRE) — A new study comparing open surgery, video-assisted thoracic surgery (VATS), and robotic-assisted surgery to remove diseased lung tissue found that robotic-assisted surgery is associated with significantly lower death rates, lower overall complication rates, and shorter hospital stays compared with open surgery. Researchers also concluded that robotic-assisted surgery is an […]

Roche and Polyphor join efforts to combat multi-drug-resistant bacterial infections

, , ,

Basel, 4 November 2013 – Roche licenses investigational antibiotic POL7080 from Polyphor. POL7080 targets Pseudomonas species with a novel mode of action. This “superbug” bacterium is commonly found in hospitals and has evolved to become resistant to many antibiotic treatments. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Polyphor Ltd., a privately held pharmaceutical company, announced today […]

«‹ 97 98 99 100›»